NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term treatment, with the dose depending on the patient. For endometriosis, they ...
A significant number of people are discharged after hospital treatment for trauma or orthopaedic surgery with temporary lower limb immobilisation. These people may have an increased risk of VTE, but ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Technology appraisal guidance TA987 Published: 10 July 2024 Register as a ...
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...
An aligned pathway between the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE, along with an improved advice service, will help bring medicines to patients faster and give ...
Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. There is a commercial access ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
This guidance has been updated and replaced by NICE's technology appraisal guidance on trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results